Satellos Bioscience Inc.

TSX:MSCL.TO

Biotechnology

Healthcare
$8.62 +0.12%

+$0.01 today

Market cap
$182.89M
Beta
1.17
P/E (TTM)
-1.8
EPS (TTM)
-$0.32
52W Low $6.36High $18.98

Volume 0.01M

Average 0.02M

MSCL.TO Selling, General & Admin

Overhead costs of running the business, including sales, marketing, management, and administrative staff.

Satellos Bioscience Inc.TSX: MSCL.TO

Selling, General & Admin · Q1 FY2026 · quarter ended Mar 2026

Selling, general & admin grows 86.4% year over year

Q1 FY2026 selling, general & admin of $2.35M rose 86.4% year over year. Sequentially, it rose 5.4% from the prior quarter. Over 3 fiscal years it compounded at +10.7% a year.

Context

  • Selling, general & admin increased in 2 of the last 3 fiscal years.

What to watch

Whether selling, general & admin reaches the consensus estimate of $0 (-100.0%) for the fiscal year ending Dec 2026, a slowdown from the -9.1% reported in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
$2.35M+5.4% QoQ
Last fiscal yearDec 2025
$7.44M-9.1% YoY
LTMMar 2026
$7.71M— YoY
Selling, General & Admin past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+86.4%-100.0%-186.4 pp
1 year-9.1%-100.0%-90.9 pp
3-year CAGR+10.7%——
5-year CAGR——
10-year CAGR——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Selling, General & Admin history

Mixed currencies · from the income statement

Latest · FY2025
7.44M USD
Year-over-year change
—
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Selling, General & Admin vs competitors

How MSCL.TO compares with its peers on the latest reported figures

  • Peers report in different currencies, so selling, general & admin is compared through growth and share of revenue rather than absolute size.
  • Over three fiscal years its annual growth of +10.7% compares with a peer median of -1.4%.
MSCL.TO Competitors
Selling, General & Admin for MSCL.TO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CRDL.TOCardiol Therapeutics Inc.LTM Mar 2026CA$20.28M CAD-21.3%-3.4%—
MSCL.TOSatellos Bioscience Inc.LTM Mar 2026$7.71M USD—+10.7%—
SVA.TOSernova Corp.LTM Apr 2026CA$6.87M CAD-16.6%-1.4%—
HBP.TOHelix BioPharma Corp.LTM Apr 2026CA$1.67M CAD-34.6%+45.7%—
Peer median (excluding MSCL.TO) —-21.3%-1.4%—

Competitors are the stored peer set for MSCL.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

Mixed currencies
Metric
FY2021
Dec 2021 · CAD
FY2022
Dec 2022 · CAD
FY2023
Dec 2023 · CAD
FY2024
Dec 2024 · CAD
FY2025
Dec 2025 · USD
Revenue00000
Cost of Revenue165.69K3.73M8.82M20K5.09K
Gross Profit(165.69K)(3.73M)(8.82M)(20K)(5.09K)
Gross Margin—————
Research & Development1.88M2.59M8.82M19.6M18.75M
Selling, General & Admin2.8M5.49M6.64M8.19M7.44M
Operating Expenses4.7M4.69M15.46M27.79M26.92M
Depreciation & Amortization165.69K337K7K20K5.09K
EBITDA(4.6M)(8.09M)(15.71M)(28.08M)(26.92M)
EBITDA Margin—————
Operating Income(6.65M)(8.43M)(15.46M)(27.81M)(26.92M)
Operating Margin—————
Interest Income7.99K63K1.33M1.37M1.38M
Interest Expense985.33K0177K00
Other Income / Expenses(8.86M)(2.89M)(426K)(291K)1.79M
Income Before Tax(15.51M)(11.32M)(15.89M)(28.1M)(25.13M)
Pre-Tax Margin—————
Income Tax Expense(42.41K)5K00175.01K
Net Income(15.51M)(11.32M)(15.89M)(28.1M)(25.31M)
Net Margin—————
EPS (Basic)(7.73)(3.81)(2.21)(2.94)(1.73)
EPS (Diluted)(7.73)(3.81)(2.21)(2.94)(1.73)
Weighted Avg Shares2.01M2.97M7.2M9.56M14.6M
Weighted Avg Shares (Diluted)2.01M2.97M7.2M9.56M14.6M

Satellos Bioscience Inc.

TSX:MSCL.TO

Intrinsic Alpha fair value

Locked

Current Price

$8.62

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.